Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) CAO Sells 10,679 Shares of Stock

Key Points

• Teva CAO Amir Weiss sold 10,679 shares on May 6 at an average price of $36 for proceeds of $384,444, cutting his direct ownership by 34.79% to 20,016 shares valued at $720,576.
• TEVA traded at $36 (near its 52‑week high of $37.35) with a market cap of $41.39 billion, a P/E of 27.07, and recent 50‑/200‑day moving averages of $31.24 and $29.69.
• Analysts have raised several price targets (e.g., Truist to $45, JPMorgan to $40, BofA to $42) and the consensus rating is a Moderate Buy with an average target of $41.78.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares of the company's stock, valued at $720,576. This represents a 34.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded down $0.34 during trading hours on Thursday, hitting $36.00. The company's stock had a trading volume of 8,660,144 shares, compared to its average volume of 8,247,391. The business has a 50 day simple moving average of $31.24 and a two-hundred day simple moving average of $29.69. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The company has a market cap of $41.39 billion, a price-to-earnings ratio of 27.07, a PEG ratio of 3.47 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

TEVA has been the topic of a number of research analyst reports. Truist Financial upped their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an "overweight" rating in a research note on Thursday, April 30th. Barclays upped their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an "overweight" rating in a research note on Wednesday. Wall Street Zen lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Finally, Bank of America upped their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday, April 9th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of "Moderate Buy" and an average target price of $41.78.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 2.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company's stock valued at $1,384,216,000 after purchasing an additional 1,004,941 shares during the period. Phoenix Financial Ltd. increased its position in Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock valued at $834,164,000 after buying an additional 3,533,800 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its position in Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company's stock valued at $786,190,000 after buying an additional 427,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock valued at $1,171,378,000 after buying an additional 5,917,423 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries by 14.8% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company's stock valued at $1,167,323,000 after buying an additional 4,820,000 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.